SEC Form 4 · accession 0001140361-26-036379

AtaiBeckley Inc. · ATAI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 11, 2026

Accepted (ET)

Sep 11, 2026 · 5:44 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0002081043

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option^F2,F1	$1.35	Sep 11, 2026	D	48,858	D	—	Jun 7, 2030	Common Stock	48,858	D
Stock Option^F2	$1.35	Sep 11, 2026	D	404,869	D	—	Jul 8, 2030	Common Stock	404,869	D
Stock Option^F2	$1.35	Sep 11, 2026	D	62,394	D	—	Oct 20, 2032	Common Stock	62,394	D
Stock Option^F2	$4.48	Sep 11, 2026	D	103,000	D	—	Nov 5, 2035	Common Stock	103,000	D
Stock Option^F2	$4.50	Sep 11, 2026	D	121,968	D	—	Jun 4, 2036	Common Stock	121,968	D

F1Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).